ArticleBMJ open respiratory research2025
The impact of the eosinophil on the risk of acute exacerbation in asthma patients.
Article in BMJ open respiratory research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effect of GLP-1RA on blood eosinophil levels in adults: a real-world study.BMC pulmonary medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute exacerbations profoundly influence asthma prognosis, yet large-scale data linking baseline blood eosinophil counts to both short-term and long-term exacerbation risk remain limited. We therefore examined this association in one of the largest nationwide cohorts.
methodsUsing Taiwan's asthma pay-for-performance database linked to nationwide claims, we conducted a retrospective cohort study of adults with asthma (2015-2020). Baseline peak eosinophil counts defined two groups: high (≥300 cells/µL) and low (<300 cells/µL). Propensity-score matching (1:1) yielded two balanced subcohorts. Multivariable Cox models estimated adjusted HRs (aHRs) for moderate (outpatient, steroid-treated) and severe (Emergency Department visit or hospitalisation) exacerbations within 1 year and over the entire follow-up, controlling for age, sex, Charlson comorbidity score and propensity score.
resultsAmong 407 725 and 961 268 asthma patients in the high and low eosinophil groups, respectively, matched subgroups of 50 360 patients each were analysed. The high eosinophil group had higher rates of severe acute exacerbations (SAEs) within 1 year (14.67 vs 10.950 per 100 person-years) with an adjusted HR of 1.392. Similar trends were observed for moderate acute exacerbations (AEs) (HR 1.548) and all AEs (HR 1.373) within 1 year. These associations persisted after adjustment for age, gender, Charlson comorbidity score and propensity score.
conclusionsIn this first nationwide, propensity-matched cohort exceeding 100 000 adults, elevated blood eosinophil counts independently predicted both short-term and long-term moderate-to-severe asthma exacerbations across all age and sex strata. Peak eosinophil measurement thus offers a practical biomarker for early identification of high-risk patients who may benefit from intensified anti-eosinophilic or inhaled corticosteroid/long-acting beta agonist-based strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.